TY - JOUR PB - NATURE PORTFOLIO JF - npj Parkinson's Disease VL - 8 TI - Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease N1 - This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article?s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article?s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. ID - discovery10162570 UR - https://doi.org/10.1038/s41531-022-00384-x Y1 - 2022/11/12/ AV - public EP - 7 SN - 2373-8057 A1 - Batzu, Lucia A1 - Rota, Silvia A1 - Hye, Abdul A1 - Heslegrave, Amanda A1 - Trivedi, Dhaval A1 - Gibson, Lucy L A1 - Farrell, Chloe A1 - Zinzalias, Pavlos A1 - Rizos, Alexandra A1 - Zetterberg, Henrik A1 - Chaudhuri, K Ray A1 - Aarsland, Dag KW - Science & Technology KW - Life Sciences & Biomedicine KW - Neurosciences KW - Neurosciences & Neurology KW - NONMOTOR SYMPTOMS SCALE KW - ALZHEIMERS-DISEASE KW - TAU KW - BIOMARKER KW - IMPAIRMENT KW - PREDICTION KW - DIAGNOSIS KW - ACCURACY KW - DEMENTIA KW - DECLINE N2 - Early identification of cognitive impairment in Parkinson?s disease (PD) has important clinical and research implications. The aim of our study was to investigate the role of plasma tau phosphorylated at amino acid 181 (p-tau181) and plasma neurofilament light chain (NfL) as biomarkers of cognition in PD. Baseline concentrations of plasma p-tau181 and NfL were measured in a cohort of 136 patients with PD and 63 healthy controls (HC). Forty-seven PD patients were followed up for up to 2 years. Cross-sectional and longitudinal associations between baseline plasma biomarkers and cognitive progression were investigated using linear regression and linear mixed effects models. At baseline, plasma p-tau181 concentration was significantly higher in PD subjects compared with HC (p = 0.026). In PD patients, higher plasma NfL was associated with lower MMSE score at baseline, after adjusting for age, sex and education (p = 0.027). Baseline plasma NfL also predicted MMSE decline over time in the PD group (p = 0.020). No significant association between plasma p-tau181 concentration and baseline or longitudinal cognitive performance was found. While the role of p-tau181 as a diagnostic biomarker for PD and its relationship with cognition need further elucidation, plasma NfL may serve as a feasible, non-invasive biomarker of cognitive progression in PD. ER -